Laboratory Products

  • ADC Service to Accelerate Pre-clinical Conjugation Candidate Selection Announced

ADC Service to Accelerate Pre-clinical Conjugation Candidate Selection Announced

Oct 09 2019 Read 656 Times

Merck has introduced its ADC Express TM services for the rapid production of ADCs, which can reduce the time needed to produce development grade constructs for target molecule identification. With more than 70% of ADC projects outsourced to CDMOs, this crucial and streamlined service enhances Merck’s offering of process development, analytical development, testing services and manufacturing or supply of linkers, cytotoxins/payloads and conjugates.
 
Merck is committed to working with ADC innovators to speed the delivery of potential new cancer treatments to patients. The company has been at the forefront of ADC manufacturing for the last decade and is one of the few CDMOs offering pre-clinical ADC development and other development and GMP services globally.
 
Merck’s established platform technology can efficiently turn an antibody, linker and payload into an ADC. The company offers a platform approach to ADC constructs and bioconjugation, resulting in increased flexibility and speed. 
 
ADC ExpressTM services include: mini-prep scale - 10–20 mg ADC construct ± column purification; medium-prep scale - ~100 mg ADC ± column purification; certificate of testing with key quality attributes, including ADC concentration, payload density/DAR (drug antibody ratio) and monomer/aggregate content and free residual payload.
 
For companies that have a rich pipeline of monoclonal antibodies (mAbs) and want to enter the ADC space, Merck’s ADC Express TM services allow them to obtain ADCs without having to invest in potent handling capabilities. Companies can either bring their own linker technology or procure a linker payload from Merck.
 
Traditionally, several CDMOs across the globe were involved in the development and production of ADC programs. Merck’s comprehensive ADC service portfolio combines the crucial steps of drug development and production: mAb solutions, linker, payload and the final conjugation - all from a single source. 
 
Merck has more than 35 years’ experience handling biological molecules and small molecules (including highly active or potent molecules), performing conjugation and complex analytical testing and manufacturing, reducing complexity for customers. 

More information online

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment




Digital Edition

Labmate UK & Ireland April 2020

April 2020

In This Edition Articles - Export experts talk Corona Virus - Automated cell counting shouldn’t cost the earth Laboratory Products - Spectrophotometer Linearity Validation - Analysi...

View all digital editions

Events

ASMS Conference - ONLINE EVENT

May 31 2020 Houston, TX, USA

PREP 2020 - EVENT CANCELLED

May 31 2020 Baltimore, MD, USA

Laborama 2020 - ONLINE EVENT

Jun 11 2020 Brussels, Belgium

HPLC 2020 - EVENT CANCELLED

Jun 20 2020 San Diego, CA, USA

MedtecLIVE - ONLINE EVENT

Jun 30 2020 Nuremberg, Germany

View all events